|
|
Gut microbiota determine insulin sensitivity
|
|
|
|
Overview
|
|
|
|
Gutmicrobiota in health and disease
|
|
|
|
Metabolic active acterial phylae
|
|
|
|
Gut microbiota
|
|
|
|
Gut microbiota
|
|
|
|
Human microbiome projects
|
|
|
|
Symbiont role
|
|
|
|
Germfree mice and metabolism
|
|
|
|
Specific gut microbiota seem to affect body fat composition
|
|
|
|
Gutmicrobiota habit is a Transmissible trait
|
|
|
|
Gut microbiota in human disease
|
|
|
|
Gutmicrobiota products in plasma associated with developing insulin resistance and CVD
|
|
|
|
Human gutmicrobiota and enterotypes
|
|
|
|
Enterotypes and dietary composition
|
|
|
|
Gutmicrobiota in gutphysiology
|
|
|
|
Microbiota products and insulin resistance
|
|
|
|
Microbiota products and cardiovascular disease
|
|
|
|
|
|
Manipulating gutmicrobiota by fecal transplant: effect on insulin resistance
|
|
|
|
Objectives FATLOSE trial
|
|
|
|
Donors
|
|
|
|
FATLOSE trial (Faecal Administration To LOSE metabolic syndrome)
|
|
|
|
|
Outcome measures
|
|
|
|
Baseline characteristics
|
|
|
|
Effect donorfaeces on intake/metabolism:
|
|
|
|
Effect donor faeces on whole body insulin sensitivity
|
|
|
|
Effect donor faeces on hepatic insulin sensitivity
|
|
|
|
Changes in fecal butyrate and proprionate
|
|
|
|
Effect donorfaeces on gutmicrobiota
|
|
|
|
Fecal samples before and after lean donor Tx
|
|
|
|
Small intestinal biopsy before and after lean donor Tx
|
|
|
|
Caution
|
|
|
|
Manipulating gutmicrobiota by broad spectrum antibiotics : effect on insulin resistance
|
|
|
|
Antibiotic use and obesity
|
|
|
|
Study protocol
|
|
|
|
Baseline characteristics AV trial- Median (range)
|
|
|
|
Periferal insulin resistance
|
|
|
|
Hepatic insulin resistance
|
|
|
|
Gut microbiota and human metabolism
|
|
|
|
Take home message
|
|
CVC_nieuwdorp_def (PDF 2,4MB)
Deel deze pagina met collega's en vrienden: